Cullinan Therapeutics to Participate in Upcoming Investor Conferences
Cullinan Therapeutics (Nasdaq: CGEM) has announced its participation in two major upcoming investor conferences in March 2025. The company's leadership team, including Chief Executive Officer Nadim Ahmed and Chief Medical Officer Jeffrey Jones, will engage in fireside chats at both events.
The first appearance will be at the TD Cowen 45th Annual Health Care Conference in Boston on March 4, 2025, at 11:10 a.m. ET. The second presentation is scheduled for the Leerink Partners Global Healthcare Conference in Miami Beach on March 11, 2025, at 11:20 a.m. ET.
Investors and interested parties can access webcasts of both fireside chats through the Events and Presentations section of Cullinan's investor relations website.
Cullinan Therapeutics (Nasdaq: CGEM) ha annunciato la sua partecipazione a due importanti conferenze per investitori in programma a marzo 2025. Il team di leadership dell'azienda, incluso il CEO Nadim Ahmed e il CMO Jeffrey Jones, parteciperà a conversazioni informali in entrambi gli eventi.
La prima apparizione sarà alla 45ª Conferenza Annuale sulla Salute di TD Cowen a Boston il 4 marzo 2025, alle 11:10 ET. La seconda presentazione è programmata per la Conferenza Globale sulla Salute di Leerink Partners a Miami Beach l'11 marzo 2025, alle 11:20 ET.
Investitori e parti interessate possono accedere alle trasmissioni web di entrambe le conversazioni informali attraverso la sezione Eventi e Presentazioni del sito web delle relazioni con gli investitori di Cullinan.
Cullinan Therapeutics (Nasdaq: CGEM) ha anunciado su participación en dos importantes conferencias para inversores que se llevarán a cabo en marzo de 2025. El equipo de liderazgo de la compañía, que incluye al CEO Nadim Ahmed y al CMO Jeffrey Jones, participará en charlas informales en ambos eventos.
La primera aparición será en la 45ª Conferencia Anual de Salud de TD Cowen en Boston el 4 de marzo de 2025, a las 11:10 a.m. ET. La segunda presentación está programada para la Conferencia Global de Salud de Leerink Partners en Miami Beach el 11 de marzo de 2025, a las 11:20 a.m. ET.
Los inversores y partes interesadas pueden acceder a las transmisiones web de ambas charlas informales a través de la sección de Eventos y Presentaciones del sitio web de relaciones con inversores de Cullinan.
컬리난 테라퓨틱스 (Nasdaq: CGEM)는 2025년 3월에 열리는 두 개의 주요 투자자 회의에 참여한다고 발표했습니다. 회사의 리더십 팀은 CEO 나딤 아흐메드와 CMO 제프리 존스를 포함하여 두 행사에서 파이어사이드 챗에 참여할 예정입니다.
첫 번째 발표는 2025년 3월 4일 오전 11시 10분 ET에 보스턴에서 열리는 TD 코웬 제45회 연례 헬스케어 회의에서 진행됩니다. 두 번째 발표는 2025년 3월 11일 오전 11시 20분 ET에 마이애미 비치에서 열리는 리어링크 파트너스 글로벌 헬스케어 회의로 예정되어 있습니다.
투자자 및 관심 있는 당사자는 컬리난의 투자자 관계 웹사이트의 이벤트 및 발표 섹션을 통해 두 개의 파이어사이드 챗 웹캐스트에 접근할 수 있습니다.
Cullinan Therapeutics (Nasdaq: CGEM) a annoncé sa participation à deux grandes conférences pour investisseurs prévues en mars 2025. L'équipe dirigeante de l'entreprise, y compris le PDG Nadim Ahmed et le directeur médical Jeffrey Jones, participera à des discussions informelles lors des deux événements.
La première apparition aura lieu lors de la 45e Conférence Annuelle sur la Santé de TD Cowen à Boston le 4 mars 2025 à 11h10 ET. La deuxième présentation est prévue lors de la Conférence Mondiale sur la Santé de Leerink Partners à Miami Beach le 11 mars 2025 à 11h20 ET.
Les investisseurs et les parties intéressées peuvent accéder aux webcasts des deux discussions informelles via la section Événements et Présentations du site Web des relations avec les investisseurs de Cullinan.
Cullinan Therapeutics (Nasdaq: CGEM) hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im März 2025 bekannt gegeben. Das Führungsteam des Unternehmens, einschließlich CEO Nadim Ahmed und CMO Jeffrey Jones, wird an informellen Gesprächen bei beiden Veranstaltungen teilnehmen.
Der erste Auftritt findet am 4. März 2025 um 11:10 Uhr ET auf der 45. jährlichen Gesundheitskonferenz von TD Cowen in Boston statt. Die zweite Präsentation ist für den 11. März 2025 um 11:20 Uhr ET auf der Global Healthcare Conference von Leerink Partners in Miami Beach geplant.
Investoren und Interessierte können die Webcasts beider informellen Gespräche über den Bereich Veranstaltungen und Präsentationen auf der Investor-Relations-Website von Cullinan abrufen.
- None.
- None.
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its participation in the following upcoming investor conferences:
- Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston, MA on Tuesday, March 4, 2025, at 11:10 a.m. ET.
- Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami Beach, FL on Tuesday, March 11, 2025, at 11:20 a.m. ET.
Webcasts of the fireside chats will be available under the Events and Presentations section of the Company’s investor relations website at https://cullinantherapeutics.com/events-and-presentations/.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. Cullinan has strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer. Cullinan’s portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of autoimmune and cancer indications. We push conventional boundaries from candidate selection to differentiated therapeutic, applying rigorous go/no go criteria at each stage of development to fast-track only the most promising molecules to the clinic and, ultimately, commercialization. With deep scientific expertise, our teams exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow us on LinkedIn and X.
Contacts:
Investor Relations
Nick Smith
+1 401.241.3516
nsmith@cullinantx.com
Media
Rose Weldon
+1 215.801.7644
rweldon@cullinantx.com
FAQ
When is Cullinan Therapeutics (CGEM) presenting at the TD Cowen Healthcare Conference in March 2025?
What is the schedule for CGEM's presentation at the Leerink Partners Conference in March 2025?
How can investors access Cullinan Therapeutics' (CGEM) conference presentations in March 2025?
Which executives from Cullinan Therapeutics (CGEM) will be presenting at the March 2025 investor conferences?
